Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Adenomatous Polyposis Coli: early-phase trial registry

1 of 2 indexed Adenomatous Polyposis Coli trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Adenomatous Polyposis Coli: 2 US clinical trials tracked, 1 recruiting.

Adenomatous Polyposis Coli is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Parabilis Medicines, running 1 of these trials.

Enrollment posture brief

Registry condition adenomatous-polyposis-coli

OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Adenomatous Polyposis Co (th…50%
Open-enrollment share among volume-matched conditions near Adenomatous Polyposis Coli

Adenomatous Polyposis Coli lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Adenomatous Polyposis Coli on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Adenomatous Polyposis Coli is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Adenomatous Polyposis Coli records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo B Drug
1 trials
Placebo A Drug
1 trials
Sulindac Drug
1 trials
Erlotinib Drug
1 trials
Trifluridine/tipiracil Drug
1 trials
mFOLFOX-6 Drug
1 trials
FOG-001 Drug
1 trials
Nivolumab Drug
1 trials

US sites by state

Facility locations filed on Adenomatous Polyposis Coli trials. A trial with sites in several states counts in each.

Utah 1 trials
Texas 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
Oregon 1 trials
Ohio 1 trials
New York 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Adenomatous Polyposis Coli page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Adenomatous Polyposis Coli trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Parabilis Medicines sponsors the most Adenomatous Polyposis Coli trials on record, review their full trial history before evaluating a specific study. See Parabilis Medicines's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adenomatous Polyposis Coli condition card totals 2 registered trials; most-linked intervention Placebo B; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.